The Shanghai Food and Drug Safety Commission issued the “Fifteenth Five-Year Plan” for Ensuring Drug Safety and Promoting High-Quality Development of the Pharmaceutical Industry in Shanghai. Among them, it is mentioned that by 2030, Shanghai Drug Administration will “consolidate the foundation and expand energy, improve quality and efficiency, and achieve an overall leap forward.” The chain of responsibility has been improved, and a comprehensive system of responsibility for shared responsibility between the party and government, departmental coordination, corporate responsibility, and common social governance has been established. Risk prevention and control has been strengthened, the dynamic safety supervision mechanism throughout the process continues to be consolidated, and systemic and regional safety risks have been effectively prevented. Reform efforts have been deepened, the reform of the review and approval system has been advanced in depth, and breakthroughs have been made in pilot reforms in key areas. The service supply is of higher quality, the working mechanism for biomedical development service innovation has been continuously improved, and registration guidance and service efficiency have been fully released. Regulatory guarantees have been improved, the regulatory system and regulatory science system have been comprehensively upgraded, talent team building has continued to be strengthened, and digital intelligent supervision capabilities and the level of internationalization of supervision have improved markedly. Better serve Shanghai to build a highland of innovation in the biomedical industry with international influence, and better meet the health needs of the masses.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.